Advertisement

Psychopharmacology

, Volume 52, Issue 1, pp 47–53 | Cite as

Propranolol effects on acute marihuana intoxication in man

  • A. Sulkowski
  • L. Vachon
  • E. S. RichJr.
Human Pharmacology

Abstract

To investigate the possible interaction of a beta adrenergic blocking agent and marihuana, six healthy experienced marihuana smokers received the two drugs separately and in combination. Propranolol (120 mg per os) reduced resting HR and BP; there were no changes in performance on tasks designed to test psychomotor speed, attention, memory and learning. Marihuana (10 mg Δ9-THC), administered in smoke, induced the typical subjective state (“high”) with marked increases in HR, BP and conjunctival injection; it impaired performance on a learning test without significantly affecting attention. Pre-treatment with propranolol blocked effectively the cardiovascular effects of marihuana; it prevented the learning impairment and, to a lesser degree, the characteristic subjective experience.

Key words

Marihuana Propranolol Subjective drug effects Attention Learning 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abel, E. L.: Retrieval of information after use of marihuana. Nature (Lond.) 231, 58–60 (1971)Google Scholar
  2. Alexander, R. W., Davis, J. N., Lefkowitz, R. J.: Direct identification and characterization of β-adrenergic receptors in rat brain. Nature (Lond.) 258, 437–440 (1975)Google Scholar
  3. Beaconsfield, P., Ginsburg, J., Rainsbury, R.: Marihuana smoking, Cardiovascular effects in man and possible mechanisms. New Engl. J. Med. 287, 209–212 (1972)Google Scholar
  4. Braude, M. C., Szara, S. (eds.): The pharmacology of marihuana. New York: Raven Press 1976Google Scholar
  5. Burstein, S., Levin, E., Varanelli, C.: Prostaglandis and cannabis. II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem. Pharmacol. 22, 2905–2910 (1973)Google Scholar
  6. Cavero, I., Hoffman, F.: Cardiovascular effects of (−) Δ 9-transtetrahydrocannabinol (THC) in the dog. Presented at the Internat'l Conf. on the Pharmacology of Marihuana, Savannah, Ga., Dec. 1974Google Scholar
  7. Clark, L. D., Nakashima, E. N.: Experimental Studies of Marihuana. Amer. J. Psychiat. 125, 379–384 (1968)Google Scholar
  8. Clark, S. C.: Marihuana and the cardiovascular system. Pharm Biochem. Behav. 3, 299–306 (1975)Google Scholar
  9. DeLong, F. L., Levy, B. I.: Cognitive effects of marijuana, described in terms of a model of attention. Psychol. Rep. 33, 907–316 (1973)Google Scholar
  10. Dornbush, R. L.: Marihuana and memory: Effects of smoking on storage. Trans. N.Y. Acad. Sci. 36, 94–100 (1974)Google Scholar
  11. Drew, W. G., Kipplinger, G. F., Miller, L. L., Marx, M.: Effects of propranolol on marihuana-induced cognitive dysfunctioning. Clin. Pharmacol. Ther. 13, 526–533 (1972)Google Scholar
  12. Drew, W. G., Miller, L. L.: Cannabis: Neural mechanisms and behavor—a theoretical review. Pharmacology 11, 12–32 (1974)Google Scholar
  13. Dunleavy, D. L. F., Maclean, A. W., Oswald, I.: Debrisoquine, guanethidine, propranolol and human sleep. Psychopharmacologia (Berl.) 21, 101–110 (1971)Google Scholar
  14. Ishizaki, T., Privitera, P. J., Walle, T., Gaffney, T. E.: Cardiovascular actions of a new metabolite of propranolol: Isopropylamine. J. Pharmacol. exp. Ther. 189, 626–632 (1974)Google Scholar
  15. Kaymakçalan, S., Ercan, Z. A., Turker, R. K.: The evidence of the release of prostaglandin-like material from rabbit kidney and guinea-pig lung by (−)trans-delta-9-tetrahydrocannabinol. J. Pharm. Pharmacol. 27, 564–568 (1975)Google Scholar
  16. Keppel, G.: Design and analysis: A researcher's handbook, p. 425. Englewood Cliffs: Prentice-Hall 1973Google Scholar
  17. Lader, M. H., Tyrer, P. J.: Central and peripheral effects of propranolol and sotalol in normal human subjects. Brit. J. Pharmacol 45, 556–560 (1972)Google Scholar
  18. Marihuana and Health, Report to Congress from the Secretary, U.S. Department of Health, Education and Welfare. Washington, D.C. Government Printing Office 1971Google Scholar
  19. Marihuana and Health, Second Annual Report to Congress from the Secretary of Health, Education and Welfare. Washington, D.C.: Government Printing Office 1972Google Scholar
  20. Marihuana and Health, Third Annual Report to Congress from the Secretary of Health, Education and Welfare. Washington, D.C.: Government Printing Office 1973Google Scholar
  21. Marihuana and Health, Fourth Annual Report to the Congress from the Secretary of Health, Education and Welfare. Washington, D.C.: Government Printing Office 1974Google Scholar
  22. Melges, F. T., Tinklenberg, J. R., Deardorff, C. M., Davies, N. H., Anderson, R. E., Owen, C. A.: Temporal disorganization and delusional-like ideation. Processes induced by hashish and alcohol. Arch. gen. Psychiat. 30, 855–861 (1974)Google Scholar
  23. Melges, F. T., Tinklenberg, J. R., Hollister, L. E., Gillespie, H. K.: Temporal disintegration and depersonalization during marihuana intoxication. Arch. gen. Psychiat. 23, 204–210 (1970)Google Scholar
  24. Mendelson, J. H., Rossi, A. M., Bernstein, J. G., Kuehnle, D.: Propranolol and behavior of alcohol addicts after acute alcohol ingestion. Clin. Pharmacol. Ther. 15, 571–578 (1974)Google Scholar
  25. Myers, M. G., Lewis, P. J., Reid, J. L., Dollery, C. T.: Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. J. Pharmacol. exp. Ther. 192, 327–335 (1975)Google Scholar
  26. Nies, A. S., Shand, D. G.: Clinical pharmacology of propranolol. Circulation 52, 6–15 (1975)Google Scholar
  27. Saelens, D. A., Walle, T., Privitera, P. J., Knapp, D. R., Gaffney, T.: Central nervous system effects and metabolic disposition of a glycol metabolite of propranolol. J. Pharmacol. exp. Ther. 187, 86–92 (1974)Google Scholar
  28. Sklenovsky, A., Navratil, J., Hrbek, J., Krejci, Z.: Effect of delta-9-tetrahydrocannabinol on free amino acids in brain. Activ. nerv. sup. (Praha) 16, 216–217 (1974)Google Scholar
  29. Tinklenberg, J. R. (ed.): Marijuana and health hazards: Methodological Issues in Current Research. New York: Academic Press 1975Google Scholar
  30. Turker, R. K., Kaymakcalan, S., Ercan, Z. S.: Antihistaminic action of (−)-Trans-delta-9-tetrahydrocannabinol. Arch. int. Pharmacodyn. 214, 254–262 (1975)Google Scholar
  31. Vachon, L., Sulkowski, A., Rich, E.: Marihuana effects on learning, attention, and time estimation. Psychopharmacologia (Berl.) 39, 1–11 (1974)Google Scholar
  32. Vachon, L., Sulkowski, A.: Attention, learning and speed in psychomotor performance after marihuana smoking. In: The pharmacology of marihuana, M. C. Braude and S. Szara, eds., pp. 449–552. New York: Raven Press 1976Google Scholar
  33. Volavka, J., Dornbush, R., Feldstein, S., Clare, G., Zaks, A., Fink, M., Freedman, A. M.: Marijuana, EEG and behavior. Ann. N.Y. Acad. Sci. 191, 206–215 (1971)Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • A. Sulkowski
    • 1
  • L. Vachon
    • 1
  • E. S. RichJr.
    • 1
  1. 1.Psychiatric Research LaboratoryBoston University School of MedicineBostonUSA

Personalised recommendations